A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors

Stopped early · Phase 1/Phase 2

Conditions studied: Advanced Solid Cancers, Metastatic Cancer

In brief

The purpose of this study is to determine safety, tolerability and maximum tolerated dose of BMS-863233 in subjects advanced and/or Metastatic solid tumors.

Key facts

Study ID

NCT00886782

Run by

Bristol-Myers Squibb

People needed

11

Starts

2009-05-31

Expected to finish

2010-08-04

Last updated by the study team

2023-04-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Women who are pregnant or breastfeeding
• Subjects with known or suspected brain metastasis, primary brain tumors, or brain as the only site of disease
• Exposure to any investigational agent within 4 weeks of study drug administration
• Subjects a history of gastrointestinal disease

Where it is running

• Dana-Farber Cancer Institute-Vendor — Boston, Massachusetts, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• Karmanos Cancer Institute — Detroit, Michigan, United States
• Local Institution - 003 — Toronto, Ontario, Canada
• Local Institution — Toronto, Ontario, Canada
• Local Institution — Villejuif, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.